Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in Europe. The aim of this study is to investigate a retrospective database assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide from primary care centers in Sweden.
Interventions
DRUGliraglutide
No treatment given.
DRUGsitagliptin
No treatment given.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients from EMR (electronic medical record) system in the primary care in Sweden * Patients equal to or more than 18 years of age * Starting treatment with liraglutide or sitagliptin from January 2010 to December 2013 * Minimum of 180 days of prior follow-up/history within the database before their index date
Exclusion criteria
* Patients with cancer, end stage liver disease, end stage renal failure (non-diabetes related) * Female patients with gestational diabetes during pregnancy * Patients with previous GLP-1 (glucagon-like peptide-1) or DPP-IV (dipeptidyl peptidase-4 ) inhibitor use, i.e. patients should be incretin naïve
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction | Day 0, Day 180 |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c (NGSP standard, in %) change | Day 0, Day 180 |
| Change in weight (in kilograms) | Day 0, Day 180 |
| Percent (%) of patients with HbA1c (glycosylated haemoglobin) reduction at least 1 %-point and weight reduction at least 3% (NICE clinical guidelines, liraglutide only) | Day 0, Day 180 |
| Change in lipids (HDL, LDL and triglycerides, in mmol/L) | Day 0, Day 180 |
| Change in creatinine | Day 0, Day 180 |
| Change in blood pressure (systolic, in mmHg) | From baseline to 180 days of therapy |
Countries
Sweden
Outcome results
None listed